The Burrill Report
The Burrill Report (July 15, 2013): Crescendo Personalizes Rheumatoid Arthritis Disease Management (.MP3,19.25 Mb)
Though the advent of personalized medicine and the changing way doctors treat and manage disease has been most apparent in the area of cancer, new molecular diagnostics are transforming care in many other disease areas. Crescendo Bioscience’s Vectra DA test for rheumatoid arthritis is one such example. We spoke to Crescendo CEO Bill Hagstrom about the test, how it’s changing the way physicians manage and treat RA patients, and how the company has addressed the challenges of adoption and reimbursement.
July 12, 2013